APA (7th ed.) Citation

Berger, U., Engelich, G., Reiter, A., Hochhaus, A., & Hehlmann, R. (2004). Imatinib and beyond - the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Annals of hematology, 83(4), . https://doi.org/10.1007/s00277-003-0807-x

Chicago Style (17th ed.) Citation

Berger, Ute, G. Engelich, Andreas Reiter, Andreas Hochhaus, and Rüdiger Hehlmann. "Imatinib and Beyond - the New CML Study IV: A Randomized Controlled Comparison of Imatinib Vs Imatinib/interferon-alpha Vs Imatinib/low-dose AraC Vs Imatinib After Interferon-alpha Failure in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia." Annals of Hematology 83, no. 4 (2004). https://doi.org/10.1007/s00277-003-0807-x.

MLA (9th ed.) Citation

Berger, Ute, et al. "Imatinib and Beyond - the New CML Study IV: A Randomized Controlled Comparison of Imatinib Vs Imatinib/interferon-alpha Vs Imatinib/low-dose AraC Vs Imatinib After Interferon-alpha Failure in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia." Annals of Hematology, vol. 83, no. 4, 2004, https://doi.org/10.1007/s00277-003-0807-x.